“BPC-157 repairs a leaky gut.”
BPC-157 has not been tested for leaky gut in people.
BPC-157 is an untested idea for leaky gut, not a treatment, and its safety in people has barely been studied. Ongoing gut symptoms are better handled by finding their cause.
If your gut symptoms keep coming back, book a visit with your doctor before trying an experimental peptide.
Safety note: Safety in people is largely unknown. In FDA's 2026 review, four-week animal studies showed possible effects on blood clotting and the liver, and injected peptides can trigger immune reactions. BPC-157 is not approved as a medicine in any country, and it is banned in sport at all times.
Talk to a healthcare professional if: your gut symptoms are persistent or getting worse, or you are thinking about using BPC-157 or another experimental peptide.
No study in people has measured whether BPC-157 changes how leaky the gut is. The only human gut trial, a small 2005 ulcerative-colitis enema study reported only as a meeting abstract, did not show a clear benefit over placebo.
BPC-157 has not been tested for leaky gut in people. Its gut-healing reputation comes from animal studies, and the one human gut trial, in ulcerative colitis, did not show a clear benefit over placebo.
In that 2005 trial, 53 people with mild to moderate ulcerative colitis used a BPC-157 enema or a placebo enema daily for two weeks; the difference between groups was small and could have been chance, and the study was never published in full. FDA's 2026 review found no studies in people of BPC-157 taken by mouth, by injection under the skin, by nasal spray or on the skin, which are the ways it is sold. A 2026 review of all human BPC-157 studies found only three small, uncontrolled studies with 30 people in total, for knee pain, bladder pain and safety, and rated the evidence very low. "Leaky gut" is also used loosely in marketing, while increased gut permeability is a measured finding in specific diseases.
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, July 23, 2026: FDA presentations on BPC-157, KPV, TB-500 and MOTS-c related bulk drug substances. FDA document 193773
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica. 2026;92(3). DOI: 10.52628/92.3.15837. PMID: 42885452
- Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. DOI: 10.3390/pharmaceutics18050625. PMID: 42198317. PMCID: PMC13210877
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In effect January 1, 2026